Study of Enfuvirtide in HIV-Positive Subjects
This study has been completed.
Information provided by:
First received: July 8, 2004
Last updated: June 23, 2005
Last verified: April 2004
A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||An Open-label, Randomized, Cross-over Study in HIV-Positive Subjects to Determine and Compare the Single-dose Pharmacokinetics of Enfuvirtide after a Single 90 mg SC Administration|
Resource links provided by NLM:
Further study details as provided by Trimeris:
Contacts and Locations